Drugs / PRO045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01826474 | Jan 2013 → Aug 2016 | Duchenne muscular dystrophy | BioMarin Pharmaceutical | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRO045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826474 ↗ |
| Route | Subcutaneous | “Subcutaneous injection” NCT01826474 ↗ |